Director/PDMR Shareholding

Gelion PLC
31 May 2023
 

 

  

Gelion plc

('Gelion' or the 'Company') 

 

Director/PDMR Shareholding

 

The Company was notified on 31 May 2023 that on 30 May, Michael Davie, Non-Executive Director, purchased 23,561 Ordinary Shares of 0.1p each ("Ordinary Shares") at a price of 35.60 pence per Ordinary Share.

 

As a result of this transaction, Michael Davie's beneficial interest in the Company is 824,242 Ordinary Shares representing 0.76 per cent of the Company's total voting rights.

 

 

Enquiries:

 

 

 

The Notification of Dealing Form set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

 

1.           

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michael Davie

2.           

Reason for the Notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3.  

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Gelion plc

b)

LEI

2138008NC7YL3MCUDR84

4.  

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 0.1p each

Identification code

GB00BNBQZD59

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 

No. of Shares

Price

23,561

£0.3560

d)

Aggregated information:

·      Aggregated volume

·      Price

See above

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Gelion (GELN)
UK 100

Latest directors dealings